



Astec LifeSciences Ltd.

Date: 30th January, 2026

To,
BSE Limited
P. J. Towers, Dalal Street, Fort
Mumbai – 400 001

Ref.: BSE Scrip Code No. “533138”

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai-400 051

Ref.: “ASTEC”

Debt Segment NSE:
NCD-ASTEC-ISIN: INE563J08023

Sub.: Press Release

The Board of Directors of Astec LifeSciences Limited (“the Company”), at its Meeting held on **Friday, 30th January, 2026**, has approved the Unaudited Financial Results (both Standalone and Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Nine Months’ period ended 31st December, 2025.

We enclose a copy of the Press Release and the same is being placed on the website of the Company.

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)

Encl.: As Above



Regd. Office :
“Godrej One”, 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236

ASTEC LIFESCIENCES LIMITED

“Godrej One”, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (E), Mumbai-400079, India

CIN: L99999MH1994PLC076236

PRESS RELEASE

Mumbai, 30th January 2026: Astec LifeSciences Limited (“Astec”) has today announced its financial results for the third quarter & nine months ended December 31, 2025.

FINANCIAL OVERVIEW

Q3 FY26 Financial Summary

- The Company reported consolidated total income of Rs. 125.5 crore in Q3FY26 as compared to Rs. 95.7 crore in Q3FY25.
- The Company reported consolidated EBITDA of Rs. 4.8 crore in Q3FY26 as compared to EBITDA loss of Rs. 3.8 crore in Q3 FY25.
- The Company reported a Loss (after exceptional items and tax) of Rs. 15.7 crore in Q3FY26 as compared to a loss of Rs. 40.4 crore in Q3FY25.

9M FY26 Financial Summary

- The Company reported consolidated total income of Rs. 292 crore in 9M FY26 as compared to Rs. 266.6 crore in 9M FY25.
- The Company reported consolidated EBITDA loss of Rs. 11.2 crore in 9M FY26 as compared to loss of Rs. 66.9 crore in 9M FY25.
- The Company reported a Loss (after exceptional items* and tax) of Rs. 73.1 crore in 9M FY26 as compared to a loss of Rs. 118.6 crore in 9M FY25.

Pursuant to the notification of four Labour Codes by the Government of India, the Group has assessed the incremental financial impact based on draft rules and ICAI guidance. The impact arising primarily from the revised wage definition—gratuity Rs. 1.7 crore and long-term compensated absences of Rs.0.4 crore —has been classified as **Exceptional Items due to its regulatory-driven and non-recurring nature, with ongoing monitoring of final rules.*

HIGHLIGHTS OF CONSOLIDATED FINANCIAL PERFORMANCE

(in Rs. crore)

Particulars	Q3FY26	Q3FY25	% Change	9M FY26	9M FY25	% Change
Total Income	125.5	95.8	31.0%	292.0	266.6	9.5%
Earnings before depreciation, interest and taxes (EBITDA)	4.8	-3.8	NM	-11.2	-66.9	NM
Profit/(Loss) (before Exceptional Items and Tax)	-13.6	-25.1	NM	-71.0	-125.3	NM
Profit/(Loss) after Exceptional items and Tax	-15.7	-40.4	NM	-73.1	-118.6	NM

NM: Not Measurable

CHAIRMAN'S COMMENTS

Commenting on the performance, Mr. N B Godrej, Chairman, Astec LifeSciences Limited, said:

*Astec delivered strong revenue growth, recording **1.3x growth over Q3 FY25** on the back of higher Enterprise volumes and improved offtake in the Contract Manufacturing segment. Sequentially, revenue increased **1.7x over Q2 FY26**, primarily driven by CDMO offtake.*

Improvement in Enterprise margins, together with higher CDMO volume offtake, contributed significantly to the overall margin improvement, resulting in a positive EBITDA of Rs.4.8 crore in Q3 FY26.

Revenue from Operations (in Rs. crore)	Q3FY26	Q3FY25	% Change	9M FY26	9M FY25	% Change
Category Breakdown						
Enterprise	46.6	34.1	36.7%	143.2	126.5	13.2%
Contract Manufacturing & New Products	77.6	59.8	29.7%	145.3	135.3	7.4%
Geography Breakdown						
Exports	86.3	69.6	23.9%	173.2	164.0	5.6%
Domestic	37.9	24.3	55.9%	115.3	97.8	17.9%

- ENDS -

About Astec LifeSciences Limited

Astec LifeSciences Limited (Astec) was incorporated in 1994 and is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. Astec has a healthy sales mix of both exports and domestic sales. Our exports are to over 18 countries including the United States and countries across Europe, West Asia, South-East Asia and Latin America and Africa.

For more information on the Company, please log on to www.godrejastec.com

For further information, please contact:

S. Varadaraj
Godrej Agrovet Limited
Email: s.varadaraj@godrejagrovvet.com
Tel No.: +91 22 2519 4864

Mugdha Khare
Astec LifeSciences Limited
Email: mugdha.khare@godrejastec.com
Tel No.: +91 22 2519 5777

Amit Pendse
Godrej Agrovet Limited
Email: amit.pendse@godrejagrovvet.com
Tel No.: +91 22 2519 4488

Disclaimer: "Some of the statements in this communication may be 'forward looking statements' within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company's operations include changes in industry structure, significant changes in political and economic environment in India and overseas, tax laws, import duties, litigation and labour relations."